Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease

Agile 3+ and Agile 4 scores, based on liver stiffness measurement (LSM) by transient elastography and clinical parameters, were recently reported to be effective in identifying advanced fibrosis and cirrhosis in nonalcoholic fatty liver disease (NAFLD). This study aimed to validate the utility of these scores in Japanese patients with NAFLD.

[1]  V. Wong,et al.  Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores , 2022, Journal of hepatology.

[2]  G. Infantino,et al.  AGILE 3+ Score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Kouichi Miura,et al.  Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities , 2022, World journal of gastrointestinal pathophysiology.

[4]  K. Cusi,et al.  American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[5]  T. Kawaguchi,et al.  Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  K. Chayama,et al.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 , 2021, Journal of Gastroenterology.

[7]  L. N. Valenti,et al.  Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. , 2021, Journal of hepatology.

[8]  Y. Takikawa,et al.  Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis , 2021, PloS one.

[9]  J. Ludvigsson,et al.  Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease , 2020, Gut.

[10]  T. Hara,et al.  The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis. , 2020, Radiology.

[11]  K. Chayama,et al.  Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study , 2019, JGH open : an open access journal of gastroenterology and hepatology.

[12]  Hirokazu Takahashi,et al.  Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study , 2019, Journal of Gastroenterology.

[13]  H. Kirikoshi,et al.  Assessment of 10‐year changes in liver stiffness using vibration‐controlled transient elastography in non‐alcoholic fatty liver disease , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[15]  T. Saibara,et al.  The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study , 2018, Journal of Gastroenterology.

[16]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[17]  T. Saibara,et al.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2015, Journal of Gastroenterology.

[18]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[19]  K. Saeian,et al.  Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. , 2011, Annals of diagnostic pathology.

[20]  H. Kirikoshi,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[22]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[23]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[24]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[25]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[26]  M. Colombo,et al.  Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. , 1986, Journal of hepatology.